231 related articles for article (PubMed ID: 27723935)
1. N-cadherin restrains PTH repressive effects on sclerostin/SOST by regulating LRP6-PTH1R interaction.
Yang H; Dong J; Xiong W; Fang Z; Guan H; Li F
Ann N Y Acad Sci; 2016 Dec; 1385(1):41-52. PubMed ID: 27723935
[TBL] [Abstract][Full Text] [Related]
2. Lipoprotein receptor-related protein 6 is required for parathyroid hormone-induced Sost suppression.
Li C; Wang W; Xie L; Luo X; Cao X; Wan M
Ann N Y Acad Sci; 2016 Jan; 1364(1):62-73. PubMed ID: 25847683
[TBL] [Abstract][Full Text] [Related]
3. N-cadherin restrains PTH activation of Lrp6/β-catenin signaling and osteoanabolic action.
Revollo L; Kading J; Jeong SY; Li J; Salazar V; Mbalaviele G; Civitelli R
J Bone Miner Res; 2015 Feb; 30(2):274-85. PubMed ID: 25088803
[TBL] [Abstract][Full Text] [Related]
4. Control of the SOST bone enhancer by PTH using MEF2 transcription factors.
Leupin O; Kramer I; Collette NM; Loots GG; Natt F; Kneissel M; Keller H
J Bone Miner Res; 2007 Dec; 22(12):1957-67. PubMed ID: 17696759
[TBL] [Abstract][Full Text] [Related]
5. Parathyroid hormone induces differentiation of mesenchymal stromal/stem cells by enhancing bone morphogenetic protein signaling.
Yu B; Zhao X; Yang C; Crane J; Xian L; Lu W; Wan M; Cao X
J Bone Miner Res; 2012 Sep; 27(9):2001-14. PubMed ID: 22589223
[TBL] [Abstract][Full Text] [Related]
6. Antagonists of LRP6 regulate PTH-induced cAMP generation.
Shi C; Li J; Wang W; Cao W; Cao X; Wan M
Ann N Y Acad Sci; 2011 Nov; 1237():39-46. PubMed ID: 22082363
[TBL] [Abstract][Full Text] [Related]
7. Combination of PTH (1-34) with anti-IL17 prevents bone loss by inhibiting IL-17/N-cadherin mediated disruption of PTHR1/LRP-6 interaction.
Mansoori MN; Shukla P; Singh D
Bone; 2017 Dec; 105():226-236. PubMed ID: 28935557
[TBL] [Abstract][Full Text] [Related]
8. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis.
Bellido T; Ali AA; Gubrij I; Plotkin LI; Fu Q; O'Brien CA; Manolagas SC; Jilka RL
Endocrinology; 2005 Nov; 146(11):4577-83. PubMed ID: 16081646
[TBL] [Abstract][Full Text] [Related]
9. Reversing LRP5-dependent osteoporosis and SOST deficiency-induced sclerosing bone disorders by altering WNT signaling activity.
Chang MK; Kramer I; Keller H; Gooi JH; Collett C; Jenkins D; Ettenberg SA; Cong F; Halleux C; Kneissel M
J Bone Miner Res; 2014 Jan; 29(1):29-42. PubMed ID: 23901037
[TBL] [Abstract][Full Text] [Related]
10. Parathyroid hormone signaling through low-density lipoprotein-related protein 6.
Wan M; Yang C; Li J; Wu X; Yuan H; Ma H; He X; Nie S; Chang C; Cao X
Genes Dev; 2008 Nov; 22(21):2968-79. PubMed ID: 18981475
[TBL] [Abstract][Full Text] [Related]
11. Disruption of LRP6 in osteoblasts blunts the bone anabolic activity of PTH.
Li C; Xing Q; Yu B; Xie H; Wang W; Shi C; Crane JL; Cao X; Wan M
J Bone Miner Res; 2013 Oct; 28(10):2094-108. PubMed ID: 23609180
[TBL] [Abstract][Full Text] [Related]
12. Control of Bone Anabolism in Response to Mechanical Loading and PTH by Distinct Mechanisms Downstream of the PTH Receptor.
Delgado-Calle J; Tu X; Pacheco-Costa R; McAndrews K; Edwards R; Pellegrini GG; Kuhlenschmidt K; Olivos N; Robling A; Peacock M; Plotkin LI; Bellido T
J Bone Miner Res; 2017 Mar; 32(3):522-535. PubMed ID: 27704638
[TBL] [Abstract][Full Text] [Related]
13. Lrp6 is a target of the PTH-activated αNAC transcriptional coregulator.
Pellicelli M; Hariri H; Miller JA; St-Arnaud R
Biochim Biophys Acta Gene Regul Mech; 2018 Feb; 1861(2):61-71. PubMed ID: 29413898
[TBL] [Abstract][Full Text] [Related]
14. PTH receptor signaling in osteocytes governs periosteal bone formation and intracortical remodeling.
Rhee Y; Allen MR; Condon K; Lezcano V; Ronda AC; Galli C; Olivos N; Passeri G; O'Brien CA; Bivi N; Plotkin LI; Bellido T
J Bone Miner Res; 2011 May; 26(5):1035-46. PubMed ID: 21140374
[TBL] [Abstract][Full Text] [Related]
15. SOST is a target gene for PTH in bone.
Keller H; Kneissel M
Bone; 2005 Aug; 37(2):148-58. PubMed ID: 15946907
[TBL] [Abstract][Full Text] [Related]
16. Co-deletion of Lrp5 and Lrp6 in the skeleton severely diminishes bone gain from sclerostin antibody administration.
Lim KE; Bullock WA; Horan DJ; Williams BO; Warman ML; Robling AG
Bone; 2021 Feb; 143():115708. PubMed ID: 33164872
[TBL] [Abstract][Full Text] [Related]
17. CCN1/Cyr61 Is Required in Osteoblasts for Responsiveness to the Anabolic Activity of PTH.
Zhao G; Kim EW; Jiang J; Bhoot C; Charles KR; Baek J; Mohan S; Adams JS; Tetradis S; Lyons KM
J Bone Miner Res; 2020 Nov; 35(11):2289-2300. PubMed ID: 32634285
[TBL] [Abstract][Full Text] [Related]
18. Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone.
Silvestrini G; Ballanti P; Leopizzi M; Sebastiani M; Berni S; Di Vito M; Bonucci E
J Mol Histol; 2007 Aug; 38(4):261-9. PubMed ID: 17549589
[TBL] [Abstract][Full Text] [Related]
19. Regulation of beta catenin signaling and parathyroid hormone anabolic effects in bone by the matricellular protein periostin.
Bonnet N; Conway SJ; Ferrari SL
Proc Natl Acad Sci U S A; 2012 Sep; 109(37):15048-53. PubMed ID: 22927401
[TBL] [Abstract][Full Text] [Related]
20. Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity.
Ellies DL; Viviano B; McCarthy J; Rey JP; Itasaki N; Saunders S; Krumlauf R
J Bone Miner Res; 2006 Nov; 21(11):1738-49. PubMed ID: 17002572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
